---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-197282"
form_type: "8-K"
ticker: "RMD"
cik: "0000943819"
company_name: "RESMED INC"
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T01:29:34.384101+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ResMed CFO Brett Sandercock retires; Aaron Bloomer appointed successor

## Summary
- Brett Sandercock retires as CFO effective May 4, 2026; remains special advisor to CEO through Dec 2027.
- Aaron Bloomer appointed CFO effective May 4; previously CFO of Exact Sciences (recently acquired by Abbott).
- Bloomer compensation: $725k salary, $150k sign-on bonus, $3.3M equity grant (RSUs/PSUs with TSR metrics).
- Resmed reiterates FY2026 guidance: gross margin 62-63%, SG&A 19-20%, R&D 6-7%, tax rate 21-23%.
- Sandercock's retirement not due to any disagreement; retains salary, benefits and equity vesting through 2027.

## SEC filing metadata
- accession: 0001193125-26-197282
- form_type: 8-K
- ticker: RMD
- cik: 0000943819
- company_name: RESMED INC
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/943819/000119312526197282/0001193125-26-197282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/943819/000119312526197282/d50610d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-197282
- JSON: https://secwatch.observer/filing/0001193125-26-197282.json
- Plain text: https://secwatch.observer/filing/0001193125-26-197282.txt

## Key facts
- Executive change
  Aaron Bloomer was appointed as Chief Financial Officer at RESMED INC.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On April 30, 2026, the Company also announced it appointed Aaron Bloomer, age 40, as Chief Financial Officer, effective May 4, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/943819/000119312526197282/0001193125-26-197282-index.htm
- Executive change
  Brett Sandercock departed as Chief Financial Officer at RESMED INC.
  - Action: retire
  - Role: Chief Financial Officer
  source text: On April 30, 2026, ResMed Inc. (the “Company”) announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/943819/000119312526197282/0001193125-26-197282-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.